The research identifies kamuvudine-9 as a non-toxic derivative of nucleoside reverse transcriptase inhibitors, which are common antiviral medications. In the study, animals receiving the compound were completely protected from neurologic deficits. The drug also shielded axons and myelin sheaths from degeneration during the course of the disease model.

"The remarkable reversal of some of MS’s most severe complications in animals, taken together with this drug’s promising safety profile, present a very compelling translational pathway," said Michael F. Chiang, director of NIH’s National Eye Institute.

Why It Matters

The study builds on earlier work regarding the compound's effects on retinal structure. A study titled "Kamuvudine-9 Protects Retinal Structure and Function in a Novel Model of Experimental Rhegmatogenous Retinal Detachment" was published in 2023 in Investigative Ophthalmology & Visual Science. The current research expands the scope of investigation to neurologic outcomes in multiple sclerosis models.

Related clinical efforts are underway for similar compounds. A Non-Randomized, Open Label, Safety and Efficacy Study is evaluating Kamuvudine-8 (K8) for the treatment of patients with Geographic Atrophy. These parallel tracks suggest ongoing interest in the therapeutic class for ocular and neurologic conditions.

Timeline

On September 23, 2026, a National Institutes of Health-funded study indicated that the experimental drug kamuvudine-9 facilitates recovery from pre-existing vision loss and paralysis in animal models of multiple sclerosis. On the same date, researchers at the University of Virginia found that kamuvudine-9 prevents the inflammasome, a cell-killing alarm system native to the brain and spinal cord, from activating.

Also on September 23, 2026, Michael F. Chiang, director of NIH’s National Eye Institute, stated that the remarkable reversal of some of MS’s most severe complications in animals, taken together with this drug’s promising safety profile, present a very compelling translational pathway. Additionally on that date, a nationwide analysis of more than 3 million patients showed reduced rates of multiple sclerosis and multiple sclerosis relapses among those receiving nucleoside reverse transcriptase inhibitors.

What's New

Research titled "The nucleoside analog kamuvudine-9 shows protective and therapeutic efficacy in a mouse model of multiple sclerosis" was published in 2026 in Science Translational Medicine. This publication provides additional detail on the protective mechanisms observed in the animal models.

Prior research established a foundation for these findings. A study titled Kamuvudine-9 Protects Retinal Structure and Function in a Novel Model of Experimental Rhegmatogenous Retinal Detachment was published in 2023 in Investigative Ophthalmology & Visual Science. The University of Virginia, a public university in Charlottesville, Virginia, conducted the recent research. A Non-Randomized, Open Label, Safety and Efficacy Study is evaluating Kamuvudine-8 (K8) for the treatment of patients with Geographic Atrophy.